This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: September 20, 1999
Last updated: May 26, 2015
Last verified: May 2015
The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine sevoflurane versus isoflurane inhalation at subanesthetic concentrations on mood, pain, and psychomotor performance.

Condition Intervention
Opioid-Related Disorders Substance-Related Disorders Drug: 15 % Nitrous oxide Drug: 0.3 % Sevoflurane Drug: 30% Nitrous oxide Drug: 0.6% Sevoflurane Other: Placebo

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • Pain intensity [ Time Frame: 30 min of inhalation ]
    Subjects underwent a 3 min cold immersion test at 30 min of inhalation and then provided response to pain intensity questionnaire

  • Psychomotor performance [ Time Frame: Baseline, 5 min of inhalation; 5, 30, 60 minutes recovery ]
    Subjects underwent psychomotor testing at baseline, during inhalation, and during recovery post inhalation

  • Cognitive performance [ Time Frame: Baseline, every 5 min during inhalation, 5, 30, & 60 min during recovery ]
    Subject underwent memory, sedation, visual analog, and drug effects testing

Enrollment: 12
Study Start Date: August 1996
Study Completion Date: November 1997
Primary Completion Date: November 1997 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Subject inhales no drug (100% oxygen)
Other: Placebo
Active Comparator: 0.3% sevoflurane Drug: 0.3 % Sevoflurane
Active Comparator: 0.6% sevoflurane Drug: 0.6% Sevoflurane
Active Comparator: 15% Nitrous oxide Drug: 15 % Nitrous oxide
Active Comparator: 30% Nitrous oxide Drug: 30% Nitrous oxide


Ages Eligible for Study:   21 Years to 39 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000259

United States, Illinois
University of Chicago, Anesthesia & Critical Care
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
National Institute on Drug Abuse (NIDA)
Principal Investigator: James Zacny, Ph.D. University of Chicago
  More Information

Anesthesiology. 1997 (in press).

Responsible Party: University of Chicago Identifier: NCT00000259     History of Changes
Other Study ID Numbers: NIDA-08391-11
R01DA008391 ( U.S. NIH Grant/Contract )
Study First Received: September 20, 1999
Last Updated: May 26, 2015

Keywords provided by University of Chicago:
nitrous oxide
subjective effects
healthy volunteer

Additional relevant MeSH terms:
Substance-Related Disorders
Opioid-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Nitrous Oxide
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Anesthetics, General
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents processed this record on August 21, 2017